Search Result
Results for "
muscular dystrophy
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P99588
-
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
-
- HY-101459
-
|
Others
|
Metabolic Disease
|
RTC13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-108753
-
AVI 4658
|
Others
|
Metabolic Disease
|
Eteplirsen (AVI 4658) is a synthetic antisense oligonucleotide. Eteplirsen can be used for Duchenne muscular dystrophy research .
|
-
-
- HY-132592A
-
WVE-210201 sodium
|
Others
|
Metabolic Disease
|
Suvodirsen sodium induces exon 51 skipping and has the potential for study Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-132592
-
WVE-210201
|
Others
|
Metabolic Disease
|
Suvodirsen (WVE-210201) is a oligonucleotide. Suvodirsen has the potential for study Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-122631
-
|
CDK
|
Others
|
TG693 is an orally active inhibitor of CLK1. TG693 regulates the mutated exon 31 of the dystrophin gene in vivo. TG693 is used in Duchenne muscular dystrophy (DMD) research .
|
-
-
- HY-132585A
-
Vesleteplirsen sodium
|
Others
|
Others
|
SRP-5051 sodium is a next-generation antisense oligonucleotide of peptide phosphorodiamidate morpholino oligomer (PPMO). SRP-5051 targeting exon 51 skipping in Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-132611A
-
SRP-4053 sodium
|
Others
|
Others
|
Golodirsen sodium is a phosphorodiamidate morpholino oligomer (PMO) that specifically targets exon 53 of dystrophin pre-mRNA. Golodirsen sodium can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-127137
-
Adenylosuccinate; Aspartyl adenylate
|
Endogenous Metabolite
|
Metabolic Disease
|
Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD) .
|
-
-
- HY-132611
-
SRP-4053
|
Others
|
Others
|
Golodirsen (SRP-4053) is a phosphorodiamidate morpholino oligomer (PMO) that specifically targets exon 53 of dystrophin pre-mRNA. Golodirsen can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-127137A
-
Adenylosuccinate tetraammonium; Aspartyl adenylate tetraammonium
|
Endogenous Metabolite
|
Metabolic Disease
|
Adenylosuccinic acid tetraammonium (Adenylosuccinate; Aspartyl adenylate) is an orally active purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid tetraammonium can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid tetraammonium has the potential for the study of duchenne muscular dystrophy(DMD) .
|
-
-
- HY-109017
-
-
-
- HY-161050
-
|
HDAC
Apoptosis
|
Cancer
|
YSR734 (Compound 21) is a covalent HDAC inhibitor with IC50 values of 110 nM, 154 nM, and 143 nM for HDAC1, HDAC2, and HDAC3, respectively. YSR734 can induce apoptosis in leukemia cells. YSR734 can induce myoblast differentiation and is used in the study of Duchenne muscular dystrophy .
|
-
-
- HY-17614
-
SMT C1100; BMN 195; VOX-C1100
|
Cytochrome P450
|
Others
|
Ezutromid (SMT C1100) is a first-in-class, orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM. Ezutromid can be used for the research Duchenne muscular dystrophy (DMD). Ezutromid inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM .
|
-
-
- HY-134377
-
ASP0367; MA-0211
|
PPAR
|
Metabolic Disease
|
Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b) .
|
-
-
- HY-14415
-
SR8278
Maximum Cited Publications
7 Publications Verification
|
REV-ERB
|
Neurological Disease
Metabolic Disease
|
SR8278 is a REV-ERBα antagonist and inhibits the REV-ERBα transcriptional repression activity with an EC50 of 0.47 μM. SR8278 is used to regulate the metabolism in organisms and study biological rhythm. SR8278 also can be used for the research of Duchenne muscular dystrophy and Alzheimer's disease .
|
-
-
- HY-152219
-
|
CDK
|
Infection
Cancer
|
CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC50 value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza .
|
-
-
- HY-132586
-
NS-065/NCNP-01
|
Nucleoside Antimetabolite/Analog
|
Metabolic Disease
|
Viltolarsen (NS-065/NCNP-01) is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
-
- HY-132586A
-
NS-065/NCNP-01 sodium
|
Nucleoside Antimetabolite/Analog
|
Metabolic Disease
|
Viltolarsen (NS-065/NCNP-01) sodium is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen sodium binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen sodium has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
-
- HY-16361A
-
CGP3466B; CGP3446 maleate; TCH346 maleate
|
Apoptosis
|
Neurological Disease
Metabolic Disease
|
Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-153324
-
|
Others
|
Others
|
PS220 (sodium) is an antisense RNA oligonucleotides. PS220 (sodium) can be used for research of treating muscular dystrophy .
|
-
-
- HY-153403
-
|
Others
|
Others
|
Activated A Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153404
-
|
Others
|
Others
|
Activated C Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153405
-
|
Others
|
Others
|
Activated DPG Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153406
-
|
Others
|
Others
|
Activated T Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153407
-
|
Others
|
Others
|
NCP2 Anchor can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 52 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-153402
-
|
Others
|
Others
|
Activated EG3 Tail can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .
|
-
-
- HY-W272699
-
|
Others
|
Metabolic Disease
|
Utrophin activator-1 (compound 3) is an utrophin upregulator with an EC50 of 1.8 μM. Utrophin activator-1 can be used for Duchenne muscular dystrophy research .
|
-
-
- HY-145724
-
Kyndrisa; GSK2402968A; PRO051
|
Others
|
Others
|
Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.
|
-
-
- HY-109134
-
TAS-205 free base
|
Prostaglandin Receptor
|
Metabolic Disease
|
Pizuglanstat (compound 3) is a prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthases (H-PGDS). Pizuglanstat can be used for myodegenerative disease research, such as muscular dystrophy .
|
-
-
- HY-150078
-
|
Others
|
Others
|
OX01914 is a water-solube and permeable utrophin modulator (upregulates utrophin protein levels), with an EC50 of 20.5 μM. OX01914 can be used in study of duchenne muscular dystrophy (DMD) .
|
-
-
- HY-150077
-
|
Others
|
Others
|
Utrophin modulator 1 is a potent utrophin modulator (upregulates utrophin protein levels), with an EC50 of 0.11 μM. Utrophin modulator 1 can be used in study of duchenne muscular dystrophy (DMD) .
|
-
-
- HY-150237
-
|
Others
|
Others
|
FITC-labeled Drisapersen (sodium) is Drisapersen labeled with FITC. Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.
|
-
-
- HY-48959
-
|
Integrin
|
Metabolic Disease
|
α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy .
|
-
-
- HY-18102
-
GLPG0492
Maximum Cited Publications
7 Publications Verification
|
Androgen Receptor
|
Others
|
GLPG0492 is a non-steroidal selective androgen receptor modulator (potency 12 nM). GLPG0492 has the potential for the research of musculo-skeletal diseases such as sarcopenia and cachexia .
|
-
-
- HY-114739
-
|
PPAR
|
Metabolic Disease
|
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC50s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) .
|
-
-
- HY-W015828
-
RGX-202; 3-Guanidinopropionic acid
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. Ompenaclid can be used for the research of cancer and duchenne muscular dystrophy .
|
-
-
- HY-132584A
-
SRP-4045 sodium
|
Others
|
Others
|
Casimersen sodium is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen sodium binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen sodium can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-132584
-
SRP-4045
|
Others
|
Others
|
Casimersen (SRP-4045) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
-
- HY-147774
-
|
Cathepsin
|
Others
|
Cathepsin K inhibitor 6 (compound 19) is an inhibitor of cathepsin K (Cat K) with an IC50 of 17 nM. Cathepsin K inhibitor 6 also has inhibitory effects on other isoforms, with IC50s of 0.05 μM (Cat L) and 0.3 μM (Cat B), respectively .
|
-
-
- HY-153369
-
|
Guanylate Cyclase
|
Cardiovascular Disease
Neurological Disease
|
BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
|
-
-
- HY-136340
-
|
Glucocorticoid Receptor
NF-κB
|
Metabolic Disease
Inflammation/Immunology
|
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an intermediate of delta 9,11 steroids synthesis, for example, Vamorolone (HY-109017). The delta 9,11 steroids are modifications of glucocorticoids and has anti-inflammatory properties. The delta 9,11 steroids are agents for protection against cell damage (lipid peroxidation) and inhibition of neovascularization .
|
-
-
- HY-147332
-
|
Liposome
|
Neurological Disease
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-147332
-
|
Drug Delivery
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10242
-
Myostatin inhibitory peptide 7
|
Peptides
|
Others
|
ACE-031 (Myostatin inhibitory peptide 7) is a recombinant protein comprised of activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin IgG1. ACE-031 exhibits inhibitory activity against myostatin and other negative regulators of muscle mass, promotes muscle growth .
|
-
- HY-P10263
-
MAGE-1(161-169), human
|
Peptides
|
Others
|
MAGE-1 nonapeptide (MAGE-1 (161-169), human) is a radioiodinated photoreactive derivative from MAGE-1 encoded melanoma tumor antigen .
|
-
- HY-P1360
-
|
Peptides
|
Metabolic Disease
|
H-D-MeAla-EtVaI-VaI-MeLeu-AIa-D-AIa-MeLeu-MeLeu-MeVaI-MeBmt(OAc)-Abu-O-CH2-CH2-NHMe is a nonimmunosuppressive cyclosporin A derivative. H-D-MeAla-EtVaI-VaI-MeLeu-AIa-D-AIa-MeLeu-MeLeu-MeVaI-MeBmt(OAc)-Abu-O-CH2-CH2-NHMe has the potential for the research of congenital muscular dystrophy .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99588
-
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
- HY-P99857
-
PF-06252616
|
Inhibitory Antibodies
|
Metabolic Disease
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
- HY-P99370
-
LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
Products |
|
Cat. No. |
|
Species |
|
Source |
|
Tag |
|
Accession |
|
Gene ID |
|
Molecular Weight |
|
Purity |
|
Endotoxin Level |
|
Biological Activity |
|
Appearance |
|
Formulation |
|
Storage & Stability |
|
Shipping |
|
Free Sample |
Yes
No
|
Size |
* This product has been "discontinued".
Optimized version of product available:
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-16361A
-
CGP3466B; CGP3446 maleate; TCH346 maleate
|
|
Alkynes
|
Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: